Nectin-2 expression on malignant plasma cells is associated with better response to TIGIT blockade in multiple myeloma E Lozano, MP Mena, T Díaz, B Martin-Antonio, S León, ... Clinical Cancer Research 26 (17), 4688-4698, 2020 | 37 | 2020 |
Acute myeloid leukemia with NPM1 mutation and favorable European LeukemiaNet category: outcome after preemptive intervention based on measurable residual … A Bataller, G Oñate, M Diaz‐Beyá, F Guijarro, A Garrido, S Vives, ... British journal of haematology 191 (1), 52-61, 2020 | 35 | 2020 |
CAR density influences antitumoral efficacy of BCMA CAR T cells and correlates with clinical outcome P Rodriguez-Marquez, ME Calleja-Cervantes, G Serrano, A Oliver-Caldes, ... Science Advances 8 (39), eabo0514, 2022 | 29 | 2022 |
European LeukemiaNet 2017 risk stratification for acute myeloid leukemia: validation in a risk-adapted protocol A Bataller, A Garrido, F Guijarro, G Oñate, M Diaz-Beyá, M Arnan, ... Blood advances 6 (4), 1193-1206, 2022 | 27 | 2022 |
First report of CART treatment in AL amyloidosis and relapsed/refractory multiple myeloma A Oliver-Caldes, R Jiménez, M Español-Rego, MT Cibeira, ... Journal for Immunotherapy of Cancer 9 (12), 2021 | 19 | 2021 |
Fractionated initial infusion and booster dose of ARI0002h, a humanised, BCMA-directed CAR T-cell therapy, for patients with relapsed or refractory multiple myeloma (CARTBCMA … A Oliver-Caldés, V González-Calle, V Cabañas, M Español-Rego, ... The Lancet Oncology 24 (8), 913-924, 2023 | 17 | 2023 |
Factors associated with the clinical outcome of patients with relapsed/refractory CD19+ acute lymphoblastic leukemia treated with ARI-0001 CART19-cell therapy V Ortiz-Maldonado, S Rives, M Español-Rego, A Alonso-Saladrigues, ... Journal for immunotherapy of cancer 9 (12), 2021 | 15 | 2021 |
Why immunotherapy fails in multiple myeloma LG Rodríguez-Lobato, A Oliver-Caldés, DF Moreno, ... Hemato 2 (1), 1-42, 2020 | 10 | 2020 |
Results from a pilot study of ARI0002h, an academic BCMA-directed CAR-T cell therapy with fractionated initial infusion and booster dose in patients with relapsed and/or … CF de Larrea, V Gonzalez-Calle, V Cabañas, A Oliver-Caldes, ... Blood 138, 2837, 2021 | 9 | 2021 |
Prognostic impact of MYD88 and CXCR4 mutations assessed by droplet digital polymerase chain reaction in IgM monoclonal gammopathy of undetermined … DF Moreno, M López‐Guerra, S Paz, A Oliver‐Caldés, MP Mena, ... British Journal of Haematology 200 (2), 187-196, 2023 | 7 | 2023 |
Real‐world data on survival improvement in patients with multiple myeloma treated at a single institution over a 45‐year period LG Rodríguez‐Lobato, A Pereira, C Fernandez de Larrea, MT Cibeira, ... British Journal of Haematology 196 (3), 649-659, 2022 | 7 | 2022 |
Long-term responders after autologous stem cell transplantation in multiple myeloma A Oliver-Caldes, JC Soler-Perromat, E Lozano, D Moreno, A Bataller, ... Frontiers in Oncology 12, 936993, 2022 | 6 | 2022 |
Grupo Cooperativo Para el Estudio y Tratamiento de las Leucemias Agudas y Mielodisplasias (CETLAM). Acute myeloid leukemia with NPM1 mutation and favorable European LeukemiaNet … A Bataller, G Onate, M Diaz-Beyá, F Guijarro, A Garrido, S Vives, M Tormo, ... Br J Haematol 191 (1), 52-61, 2020 | 6 | 2020 |
T cells isolated from G-CSF-treated multiple myeloma patients are suitable for the generation of BCMA-directed CAR-T cells AM Battram, A Oliver-Caldés, M Suárez-Lledó, M Lozano, MB i Crespo, ... Molecular Therapy-Methods & Clinical Development 26, 207-223, 2022 | 5 | 2022 |
S103: Efficacy and Safety of ARI0002H, an academic BCMA-directed CAR-T cell therapy with fractionated initial therapy and booster dose in patients with relapsed/refractory … CF De Larrea, V González-Calle, A Oliver-Caldés, V Cabañas, ... HemaSphere 6, 4-5, 2022 | 5 | 2022 |
Prognostic impact of MYD88 L265P mutation by droplet digital PCR in IgM MGUS and smoldering Waldenström macroglobulinemia DF Moreno, S Paz, MP Mena, M Lopez-Guerra, A Oliver-Caldes, ... Blood 138, 462, 2021 | 5 | 2021 |
Defining an ultra-low risk group in asymptomatic IgM monoclonal gammopathy DF Moreno, A Pereira, N Tovar, MT Cibeira, L Magnano, M Rozman, ... Cancers 13 (9), 2055, 2021 | 5 | 2021 |
Early T-cell precursor lymphoblastic leukaemia: response to FLAG-IDA and high-dose cytarabine with sorafenib after initial refractoriness A Bataller, M Garrote, A Oliver-Caldés, M López-Guerra, D Colomer, ... British journal of haematology 185 (4), 755-757, 2019 | 5 | 2019 |
Paraskeletal and extramedullary plasmacytomas in multiple myeloma at diagnosis and at first relapse: 50-years of experience from an academic institution R Jiménez-Segura, L Rosiñol, MT Cibeira, C Fernández de Larrea, ... Blood Cancer Journal 12 (9), 135, 2022 | 4 | 2022 |
Correlative biological studies related to the response, peak and persistence of ARI0002h, an academic BCMA-directed CAR-T cell, with fractionated initial infusion and booster … A Oliver-Caldés, M Español-Rego, A Zabaleta, S Inogés, ALD de Cerio, ... Blood 138, 552, 2021 | 4 | 2021 |